Biodexa Pharmaceuticals (BDRX) Total Non-Current Liabilities (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Total Non-Current Liabilities data on file, last reported at $857957.2 in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 53.06% year-over-year to $857957.2; the trailing twelve-month figure through Dec 2025 stood at $857957.2 (down 53.06% YoY), and the FY2025 full-year result was $850439.2, down 53.47% from the prior year.
• Total Non-Current Liabilities declined to $857957.2 in Q4 2025, from $1.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $2.2 million in Q2 2024 to a low of $366139.8 in Q4 2023.
• A 5-year average of $998114.6 and a median of $846861.9 in 2021 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 617.48% in 2021 and plunged 53.06% in 2025, its largest moves.
• Tracing BDRX's Total Non-Current Liabilities over 5 years: stood at $835766.6 in 2021, then plunged by 35.02% to $543065.8 in 2022, then tumbled by 32.58% to $366139.8 in 2023, then jumped by 399.18% to $1.8 million in 2024, then sank by 53.06% to $857957.2 in 2025.
• Business Quant data shows BDRX's Total Non-Current Liabilities at $857957.2 in Q4 2025, $1.2 million in Q2 2025, and $1.8 million in Q4 2024.